The MHC class III complement genes C2, factor B, C4A and C4B constitute critical elements in the classical and alternative amplification pathways that activate this important effector of host defenses and immunopathology. Cellular specific constitutive and regulated expression of these genes in tissues of endo-, meso- and ectodermal origin and the marked change in extrahepatic C2, C4 and Bf expression in human diseases requires further understanding of the molecular mechanisms controlling these phenomena. Accordingly, we propose to elucidate the structure and function of cis and trans elements governing constitutive and regulated Bf, C2, C4A and C4B gene expression. The C4A null genotype is associated with systemic lupus erythematosus and differences in response of C4A and C4B to cytokine stimulation may be in part responsible for this association. C2 and factor B are rate limiting constituents in the activation process so that local concentrations of each is critical in the balance of regulatory and effector mechanisms of particular importance will be an analysis of differences between expression of these complement genes in epithelia as opposed to mesenchymal cells because the role of complement at epithelial surfaces is only poorly understood. The availability of material from patients with C2 deficiency type II (in which a secretory block accounts for the deficiency) permits a dissection of the cellular/molecular biological basis for the disorder and will lead to an understanding of the normal C2 secretory pathway. Finally, the absence of homozygous factor B deficient individuals or experimental animals has heretofore prevented an in vivo analysis of an isolated defect in the alternative pathway. The development of gene targeting technology now allows us to generate a Bf (-/-) phenotype in mice to address these questions directly. An understanding of the regulation of class III MHC complement genes at a fundamental level offers the potential for more effective therapies of disorders characterized by chronic inflammation.

Project Start
1998-04-01
Project End
2000-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
15
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Immune Disease Institute, Inc.
Department
Type
DUNS #
115524410
City
Boston
State
MA
Country
United States
Zip Code
02115
Szilagyi, Agnes; Banlaki, Zsofia; Pozsonyi, Eva et al. (2010) Frequent occurrence of conserved extended haplotypes (CEHs) in two Caucasian populations. Mol Immunol 47:1899-904
Johnson, B A; Geha, M; Blackwell, T K (2000) Similar but distinct effects of the tristetraprolin/TIS11 immediate-early proteins on cell survival. Oncogene 19:1657-64
Libert, C; Wielockx, B; Grijalba, B et al. (1999) The role of complement activation in tumour necrosis factor-induced lethal hepatitis. Cytokine 11:617-25
Circolo, A; Garnier, G; Fukuda, W et al. (1999) Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. Immunopharmacology 42:135-49
Lokki, M L; Circolo, A; Ahokas, P et al. (1999) Deficiency of human complement protein C4 due to identical frameshift mutations in the C4A and C4B genes. J Immunol 162:3687-93
De, J; Lai, W S; Thorn, J M et al. (1999) Identification of four CCCH zinc finger proteins in Xenopus, including a novel vertebrate protein with four zinc fingers and severely restricted expression. Gene 228:133-45
Hausmann, S; Biddison, W E; Smith, K J et al. (1999) Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures. J Immunol 162:5389-97
Wang, X; Circolo, A; Lokki, M L et al. (1998) Molecular heterogeneity in deficiency of complement protein C2 type I. Immunology 93:184-91
Gauthier, L; Smith, K J; Pyrdol, J et al. (1998) Expression and crystallization of the complex of HLA-DR2 (DRA, DRB1*1501) and an immunodominant peptide of human myelin basic protein. Proc Natl Acad Sci U S A 95:11828-33
Tsitsikov, E N; Gutierrez-Ramos, J C; Geha, R S (1997) Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc Natl Acad Sci U S A 94:10844-9

Showing the most recent 10 out of 61 publications